(Reuters) - Sepracor has filed suit in the U.S. District Court of
Delaware to prevent Barr from selling its generic, Barr said.
Xopenex, one of Sepracor's biggest-selling products, had
U.S. sales of about $610 million for the 12 months ended in
May, Barr said.
Read more at Reuters.com Government Filings News
Delaware to prevent Barr from selling its generic, Barr said.
Xopenex, one of Sepracor's biggest-selling products, had
U.S. sales of about $610 million for the 12 months ended in
May, Barr said.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment